Blocking both targets can prevent cancer cells from evading exhausted T-cell immunity while simultaneously delivering signals to antigen presenting cells (APCs) that activate T-cells in the early stages, therefore strengthening the immune response [43, 44]. Furthermore, CTLA-4 inhibitors have been ...
in vivo blocking of PD-1/PD-L signaling John, L. B., et al. (2013). "Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells" Clin Cancer Res 19(20): 5636-5646 in vivo blocking of PD-1/PD-L signaling Holmgaard, R. B., et ...
(2013). "Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells" Clin Cancer Res 19(20): 5636-5646 in vivo blocking of PD-1/PD-L signaling Holmgaard, R. B., et al. (2013). "Indoleamine 2,3-dioxygenase is a critical resistance ...
CD8+T cell-dependent manner, ameliorating various ageing-related phenotypes. These results suggest that the heterogeneous expression of PD-L1 has an important role in the accumulation of senescent cells and inflammation associated with ageing, and the elimination of PD-L1+senescent cells by immune che...
(PBMCs) from HIV-infected individuals on suppressive ART with the latency reversing agent bryostatin in the presence of a PD-1 blocking antibody (pembrolizumab) or the corresponding isotype control. HIV production was greatly increased by PD-1 blockade (median fold-increase over isotype control (...
Anti-PD-1 versus anti-PD-L1/2 therapy and opportunities for combination with other immunotherapies Due to its robustness, blocking PD-1 delivers the probable risk of activating subpopulations of autoreactive and pathogenic T-cell subsets in the patient, as seen with the onset of inflammatory condi...
blocking antibody in this combination is not recommended outside of controlled clinical trials. Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. If used during pregnancy, or if the patient becomes pregnant during treatment, app...
Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.WEBER, JEFFREY, S.WANG, WENSHIYU, BIN
Combination immunotherapy with the PD-1 blocking antibody, nivolumab, and anti-CTLA-4, ipilimumab, has demonstrated higher response rates (RRs) than either therapy alone in metastatic melanoma. However, dual checkpoint blockade causes more frequent and severe irAEs, as 53% of patients experience gra...
Either blocking CD25 with an antibody or using a mutated version of IL-2 that does not bind to CD25 but still binds to CD122 and CD132 almost completely abrogated the synergistic effects observed after PD-1 + IL-2 combination therapy. There is considerable interest in PD-1 + IL-2 ...